Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which of the following does NOT induce microsomal enzymes?

Cimetidine. **Explanation:** The core concept tested here is the distinction between **Enzyme Inducers** and **Enzyme Inhibitors**. Microsomal enzymes (primarily the Cytochrome P450 system in the liver) are responsible for the metabolism of many drugs. **1. Why Cimetidine is the correct answer:** Cimetidine is a potent **Enzyme Inhibitor**. It binds to the heme iron of the CYP450 system, reducing the metabolic activity of the liver. This leads to decreased clearance and increased plasma concentrations of co-administered drugs (like Warfarin or Theophylline), potentially causing toxicity. **2. Why the other options are incorrect:** * **Phenobarbitone:** A classic, potent inducer of CYP450 enzymes. It increases the synthesis of microsomal enzymes, accelerating the metabolism of itself and other drugs. * **Rifampicin:** One of the most powerful known enzyme inducers. It significantly reduces the half-life of drugs like oral contraceptives, often leading to therapeutic failure. * **Griseofulvin:** An antifungal agent known to induce hepatic microsomal enzymes, particularly affecting the metabolism of Warfarin. **High-Yield Clinical Pearls for NEET-PG:** To remember these for the exam, use these popular mnemonics: * **Enzyme Inducers (GPRS Cell Phone):** **G**riseofulvin, **P**henytoin/Phenobarbitone, **R**ifampicin, **S**moking, **C**arbamazepine. * **Enzyme Inhibitors (VITAMIN K):** **V**alproate, **I**soniazid, **T**erfenadine, **A**miodarone, **M**ethylphenidate, **I**traconazole, **N**ight (Grapefruit) juice, **K**etoconazole (**C**imetidine and **E**rythromycin are also critical inhibitors). **Note:** Cimetidine also has anti-androgenic side effects (gynecomastia), making it a frequent topic in NEET-PG pharmacology questions.

Q: When atrial fibrillation persists despite digoxin therapy, an inadequate digoxin dose is suspected. Plasma levels of digoxin for confirmation are typically drawn after a certain interval following the last dose. Considering pharmacokinetic principles, which factor is most crucial for determining this appropriate sampling time?

Rate of distribution. **Explanation:** The correct answer is **Rate of distribution (Option B)**. This is a classic pharmacokinetic concept essential for drugs that follow a **two-compartment model**, such as digoxin. Digoxin has a prolonged distribution phase (6–8 hours). After administration, the drug initially remains in the central compartment (blood) before moving into the peripheral compartment (tissues like the myocardium). Since the pharmacological effect of digoxin occurs at the tissue level, plasma levels drawn during the distribution phase will be falsely elevated and will not correlate with the drug’s clinical effect or toxicity. Therefore, sampling must be delayed until the **distribution equilibrium** is reached to ensure the plasma concentration reflects the tissue concentration. **Why other options are incorrect:** * **Rate of absorption (A):** While absorption determines how fast a drug enters the blood, it does not dictate the equilibrium between blood and the target organ (heart). * **Rate of clearance (C) and Elimination (D):** These factors determine the **half-life** and the time required to reach **steady-state** (usually 4–5 half-lives). While they influence the maintenance dose, they do not determine the specific timing of a post-dose sample (trough level) as critically as the distribution phase does for digoxin. **High-Yield Clinical Pearls for NEET-PG:** * **Sampling Time:** For Digoxin, blood should be drawn at least **6 to 8 hours** after the last dose. * **Volume of Distribution ($V_d$):** Digoxin has a very high $V_d$ (~7 L/kg) because it binds extensively to skeletal muscle. * **Therapeutic Window:** Narrow (0.5–2.0 ng/mL). * **Toxicity Predisposition:** Hypokalemia, hypomagnesemia, and hypercalcemia increase the risk of digoxin toxicity.

Q: Which of the following is NOT a type of oxidative drug metabolism?

Glucuronidation. ### Explanation Drug metabolism (biotransformation) is divided into two main phases: **Phase I (Non-synthetic)** and **Phase II (Synthetic)**. **Why Glucuronidation is the Correct Answer:** Glucuronidation is a **Phase II reaction**. It involves the conjugation of a drug with glucuronic acid (derived from glucose) via the enzyme **UDP-glucuronosyltransferase (UGT)**. Unlike Phase I reactions, which introduce or expose functional groups, Phase II reactions attach large, polar endogenous molecules to the drug to make it water-soluble for excretion. **Why the other options are incorrect:** Options A, B, and C are all subtypes of **Phase I Oxidative reactions**, primarily mediated by the **Cytochrome P450 (CYP450)** enzyme system: * **Deamination (A):** Removal of an amino group (e.g., metabolism of Amphetamine). * **N-oxidation (B):** Addition of oxygen to a nitrogen atom (e.g., metabolism of Trimethylamine). * **N-dealkylation (C):** Removal of an alkyl group attached to a nitrogen atom (e.g., Morphine to Normorphine). **High-Yield Clinical Pearls for NEET-PG:** * **Phase I Reactions:** Oxidation (most common), Reduction, and Hydrolysis. * **Phase II Reactions:** Glucuronidation (most common Phase II), Acetylation, Methylation, and Sulfate conjugation. * **Microsomal vs. Non-microsomal:** Glucuronidation is the **only** Phase II reaction carried out by microsomal enzymes (located in the smooth ER). All other Phase II reactions are non-microsomal (cytosolic). * **Gray Baby Syndrome:** Occurs in neonates due to a deficiency of the UGT enzyme, leading to the inability to conjugate Chloramphenicol.

Q: A drug has 40% absorption and a hepatic extraction ratio of 0.6. What is the bioavailability of the drug?

16%. **Explanation** The bioavailability ($F$) of an orally administered drug is determined by the fraction of the dose absorbed from the gastrointestinal tract and the fraction that escapes first-pass hepatic metabolism. **1. Why the Correct Answer (16%) is Right:** Bioavailability is calculated using the formula: $F = f \times (1 - ER)$ Where: * **$f$ (Absorption):** 40% or 0.4 * **$ER$ (Extraction Ratio):** 0.6 * **$(1 - ER)$:** This represents the **Hepatic Bioavailability** (the fraction of the drug that survives the liver). Calculation: $F = 0.4 \times (1 - 0.6)$ $F = 0.4 \times 0.4 = 0.16 \text{ or } 16%$ Thus, only 16% of the administered dose reaches the systemic circulation. **2. Why the Incorrect Options are Wrong:** * **B (20%):** This is a distractor often reached by miscalculating the hepatic survival or averaging the numbers. * **C (24%):** This is the result of multiplying 40% by 0.6 ($0.4 \times 0.6 = 0.24$). This represents the amount of drug **metabolized** by the liver, not the amount that reaches the circulation. * **D (28%):** This does not correlate with the mathematical relationship between absorption and extraction. **3. NEET-PG Clinical Pearls:** * **First-Pass Effect:** Drugs with a high Extraction Ratio (e.g., Nitroglycerin, Propranolol, Lidocaine) have low oral bioavailability and are often given via sublingual or IV routes. * **Bioavailability ($F$) of IV drugs:** Always 100% ($F=1$). * **Area Under the Curve (AUC):** Bioavailability is also calculated by comparing the AUC of oral administration to the AUC of IV administration ($F = \text{AUC}_{\text{oral}} / \text{AUC}_{\text{IV}}$). * **Liver Disease:** In cirrhosis, the extraction ratio decreases, which can significantly increase the bioavailability (and toxicity) of drugs with high first-pass metabolism.

Q: What does the plasma concentration versus time graph indicate?

Bioavailability. ***Bioavailability*** - The **plasma concentration versus time graph** is primarily used to calculate bioavailability by comparing the **area under the curve (AUC)** between different routes of administration (oral vs IV). - **Bioavailability (F)** is determined using the formula: F = AUC_oral / AUC_IV × Dose_IV / Dose_oral, making this graph essential for **bioequivalence studies**. *Half-life* - **Half-life** is derived from the **elimination phase slope** of the plasma concentration curve, not the overall graph comparison. - It represents the time required for plasma concentration to decrease by **50%** and is calculated from a single curve's declining phase. *Clearance* - **Clearance** is calculated using the formula **Dose/AUC** and represents the volume of plasma cleared per unit time. - While the graph provides AUC data needed for clearance calculation, the graph itself doesn't directly indicate clearance. *Elimination* - **Elimination rate constant** is determined from the **slope of the terminal elimination phase** of a single concentration-time curve. - The graph comparison between routes doesn't directly measure elimination kinetics but rather **absorption and bioavailability differences**.

Q: Phase II drug metabolism reactions include all of the following EXCEPT:

Reduction. Drug metabolism (biotransformation) typically occurs in two phases to make lipophilic drugs more polar for excretion. **Phase I Reactions (Functionalization):** These reactions introduce or expose a functional group (–OH, –NH2, –SH). They include **Oxidation** (most common, via CYP450), **Reduction**, and **Hydrolysis**. * **Reduction** is a Phase I reaction; therefore, it is the correct answer to the "EXCEPT" question. Examples of drugs undergoing reduction include Chloramphenicol and Halothane. **Phase II Reactions (Conjugation):** These involve the attachment of an endogenous group to the drug to form a highly polar, inactive metabolite. * **Acetylation (Option A):** A Phase II reaction mediated by N-acetyltransferase (NAT). Important for drugs like Isoniazid, Hydralazine, and Procainamide. * **Glycine Conjugation (Option B):** A Phase II reaction. A classic example is the conversion of Salicylic acid to Salicyluric acid. * **Methylation (Option C):** A Phase II reaction mediated by methyltransferases. Examples include the metabolism of Epinephrine and Dopamine. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Phase I:** **HOR** (Hydrolysis, Oxidation, Reduction). * **Mnemonic for Phase II:** **G**ASP **M**e (Glucuronidation, Acetylation, Sulfation, Phosphorylation, Methylation). * **Glucuronidation** is the most common Phase II reaction. * **Microsomal vs. Non-microsomal:** Most Phase I enzymes are microsomal (located in the SER), while most Phase II enzymes are non-microsomal (cytosolic), with the notable exception of **Glucuronosyltransferase**, which is microsomal. * **Gray Baby Syndrome:** Occurs in neonates due to deficient Glucuronidation of Chloramphenicol.

Q: A new antifungal medication has a half-life of 6 hours. If a continuous intravenous infusion of this drug were started, how long would it take to reach 75% of steady state?

12 hours. ### Explanation The time required to reach a steady-state concentration ($C_{ss}$) during a continuous intravenous infusion is determined solely by the drug's **half-life ($t_{1/2}$)** [1]. It is independent of the dose or the rate of infusion. **The Rule of Half-Lives:** The accumulation of a drug toward steady state follows first-order kinetics [2]: * 1 Half-life $\rightarrow$ 50% of $C_{ss}$ * **2 Half-lives $\rightarrow$ 75% of $C_{ss}$** * 3 Half-lives $\rightarrow$ 87.5% of $C_{ss}$ * 4 to 5 Half-lives $\rightarrow$ >90% (Clinically considered steady state) In this question, the half-life is **6 hours**. To reach 75% of the steady state, the drug must pass through 2 half-lives. Calculation: $2 \times 6 \text{ hours} = \mathbf{12 \text{ hours}}$. --- ### Analysis of Options: * **A (3 hours):** This represents 0.5 half-lives; the drug concentration would be significantly below the therapeutic steady state. * **B (6 hours):** This is 1 half-life, at which point the drug reaches only 50% of its steady-state concentration. * **C (9 hours):** This is 1.5 half-lives, resulting in approximately 62.5% of $C_{ss}$. * **D (12 hours):** **Correct.** As calculated, 2 half-lives are required to reach 75% of $C_{ss}$. --- ### NEET-PG High-Yield Pearls: 1. **Steady State Principle:** It takes approximately **4–5 half-lives** to reach clinical steady state ($>93\%$) and the same amount of time to completely eliminate a drug from the body after stopping the infusion [1]. 2. **Loading Dose:** If a rapid therapeutic effect is needed (e.g., in emergencies), a **Loading Dose** is given to bypass the delay caused by the half-life [3]. It does not change the time to reach steady state but achieves the target concentration immediately. 3. **Formula:** $C_{ss} = \text{Infusion Rate} / \text{Clearance}$. Note that half-life is not in the formula for the *level* of $C_{ss}$, only the *time* to reach it [2].

Q: Loading dose is given for which of the following drugs?

Chloroquine. **Explanation:** The correct answer is **Chloroquine**. **1. Why Chloroquine is correct:** The primary pharmacological reason for giving a loading dose is to rapidly achieve the **steady-state plasma concentration ($C_{ss}$)** for drugs with a **large volume of distribution ($V_d$)** or a **long half-life ($t_{1/2}$)**. Chloroquine has an exceptionally high $V_d$ (approx. 13,000 L) because it extensively binds to tissues (melanin in eyes, liver, and muscles). Without a loading dose, it would take weeks to reach therapeutic levels. In clinical practice (e.g., treating malaria), a loading dose of 600 mg base is given initially, followed by 300 mg to ensure immediate therapeutic efficacy against the parasite. **2. Why other options are incorrect:** * **Diazepam:** It is a lipid-soluble benzodiazepine with a relatively rapid onset. While it has a long half-life due to active metabolites, it does not require a loading dose for its standard sedative or anxiolytic effects. * **Propranolol:** It undergoes significant first-pass metabolism. Dosage is usually titrated based on heart rate and clinical response rather than a calculated loading dose. * **Aspirin:** Used primarily for its antiplatelet (low dose) or analgesic/anti-inflammatory effects. It has a short half-life and reaches effective concentrations quickly without a loading dose. **3. High-Yield Clinical Pearls for NEET-PG:** * **Formula:** $\text{Loading Dose} = \frac{V_d \times \text{Target } C_{p}}{\text{Bioavailability (F)}}$. * **Key Concept:** Loading dose depends on **Volume of Distribution**, whereas Maintenance Dose depends on **Clearance**. * **Other drugs requiring loading doses:** Amiodarone (very high $V_d$), Digoxin, Phenytoin, and Teicoplanin. * **Caution:** Loading doses carry a higher risk of toxicity; for example, rapid IV injection of a loading dose of Phenytoin or Aminophylline can cause cardiac arrhythmias.

Question 1

Which of the following does NOT induce microsomal enzymes?

Accepted Answer

Cimetidine

Answer

Griseofulvin

Answer

Rifampicin

Answer

Phenobarbitone

Question 2

When atrial fibrillation persists despite digoxin therapy, an inadequate digoxin dose is suspected. Plasma levels of digoxin for confirmation are typically drawn after a certain interval following the last dose. Considering pharmacokinetic principles, which factor is most crucial for determining this appropriate sampling time?

Accepted Answer

Rate of distribution

Answer

Rate of absorption

Answer

Rate of clearance

Answer

Rate of elimination

Question 3

At 12 hours after intravenous administration of a bolus dose, the plasma level of a drug is 3 mg/L. If the volume of distribution (Vd) is 10 L and the elimination half-life is 6 hours, what was the dose administered?

Accepted Answer

120 mg

Answer

180 mg

Answer

240 mg

Answer

480 mg

Question 4

Which of the following is NOT a type of oxidative drug metabolism?

Accepted Answer

Glucuronidation

Answer

Deamination

Answer

N-oxidation

Answer

N-dealkylation

Question 5

A drug has 40% absorption and a hepatic extraction ratio of 0.6. What is the bioavailability of the drug?

Accepted Answer

16%

Answer

20%

Answer

24%

Answer

28%

Question 6

Which of the following is false regarding spare receptors?

Accepted Answer

They are needed for binding a drug to achieve the maximum effect.

Answer

They respond to agonists only.

Answer

They do not alter maximal efficacy.

Answer

They can be detected by finding that EC50 < Kd for the agonist.

Question 7

What does the plasma concentration versus time graph indicate?

Accepted Answer

Bioavailability

Answer

Half-life

Answer

Clearance

Answer

Elimination

Question 8

Phase II drug metabolism reactions include all of the following EXCEPT:

Accepted Answer

Reduction

Answer

Acetylation

Answer

Glycine conjugation

Answer

Methylation

Question 9

A new antifungal medication has a half-life of 6 hours. If a continuous intravenous infusion of this drug were started, how long would it take to reach 75% of steady state?

Accepted Answer

12 hours

Answer

3 hours

Answer

6 hours

Answer

9 hours

Question 10

Loading dose is given for which of the following drugs?

Accepted Answer

Chloroquine

Answer

Diazepam

Answer

Propranolol

Answer

Aspirin

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?